Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.
The analysts forecast global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.
The report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.
Purchase a Copy of the Report @ http://www.sandlerresearch.org/purchase?rname=44178
(Single User License - US $2500)
Key market driver
- Prophylactic treatment
Key market challenge
- High cost of therapy
Key market trend
- New technological advancements
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Inquire for this report @ http://www.sandlerresearch.org/inquire-before-buying?rname=44178
Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.